<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Flow diversion (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e>) can occur with an <z:hpo ids='HP_0011009'>acute</z:hpo> middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e> is thought to represent the collateral blood flow to the occluded <z:chebi fb="70" ids="34342">MCA</z:chebi> territory, but it is unclear whether or not <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e> lessens the <z:hpo ids='HP_0001297'>stroke</z:hpo> severity or leads to improved outcome </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patients with a proximal <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion were selected from the CLOTBUST trial data bank </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e> to the anterior or posterior cerebral artery was determined using transcranial Doppler ultrasound </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> severity and clinical improvement were measured using the National Institutes of Health <z:hpo ids='HP_0001297'>Stroke</z:hpo> Scale (NIHSS) scores </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We evaluated 47 patients with an isolated M1 <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion who received intravenous tissue-type plasminogen activator (t-PA) within 3 h of symptom <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e> was present in 83% of the patients </plain></SENT>
<SENT sid="7" pm="."><plain>Median baseline NIHSS scores were 15.5 in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e>- group and 18 in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e>+ group (n.s.) </plain></SENT>
<SENT sid="8" pm="."><plain>Complete recanalization rates were 25 and 25.6% (n.s.) </plain></SENT>
<SENT sid="9" pm="."><plain>In 35 patients with a persistent occlusion, the average NIHSS score reduction was 22% (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e>+) and 0.52% (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e>-) during 90 min after t-PA bolus (p=0.017), and 29 versus -25% during the first 24 h after the t-PA bolus, respectively (p=0.01) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In patients with persistent <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusions after thrombolytic treatment, arterial blood flow diversion is associated with earlier and better neurological improvement </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e> has protective effects on the ischemic brain tissue with persistent <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
</text></document>